{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-000672","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.227418+00:00","generated_at":"2026-06-26T06:14:48.741084+00:00","sec_items":["1.01","1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcturus ARCT-154 Phase 3 shows 55% efficacy vs COVID-19, 95% vs severe disease","bullets":["Two 5-mcg doses of ARCT-154 provided 55% efficacy (95% CI 46.9-61.9) against symptomatic COVID-19.","Vaccine demonstrated 95.3% efficacy (95% CI 80.4-98.9) against severe COVID-19 including deaths.","No cases of myocarditis or pericarditis reported; unsolicited adverse events comparable to placebo.","Data submitted to Vietnam Ministry of Health for EUA; ARCT-154 advancing to pivotal booster trial in major markets.","Also amended loan with Western Alliance Bank to extend interest-only payments to Aug 1, 2022, and terminated Israeli supply deal for first-gen vaccine (no penalty)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-000672","json":"https://secwatch.observer/filing/0001193805-22-000672.json","markdown":"https://secwatch.observer/filing/0001193805-22-000672.md","text":"https://secwatch.observer/filing/0001193805-22-000672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522000672/0001193805-22-000672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522000672/e621578_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:14:48.741084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}